Repeated Injection of GnRH Agonist to Reduce Ovarian Hyperstimulation Syndrome

• Status: Unknown status
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian hyperstimulation syndrome (OHSS) in high-risk patients.

However, lower oocyte yield was reported in patients with lower luteinizing hormone (LH) level post trigger with single injection of GnRH agonist, which might be related to the shorter duration and lower amount of LH induced by GnRH agonist.

Our aim is to study repeated injection of GnRH agonist for preventing OHSS and maintaining clinical outcome in high risk patients who receive controlled ovarian stimulation in GnRH antagonist protocol.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chenshiling
• Collaborators: Comprehensive Strategic Cooperation Project of Guangdong Province and Chinese Academy of Science; Comprehensive Strategic Sciences Cooperation Projects of Guangdong Province and Chinese Academy; Guangzhou Science and Technology Program key projects; National Key Basic Research Development Plan of China; National Natural Science Foundation of China
• Treatments: Deslorelin; Triptorelin Pamoate

Criteria

Inclusion Criteria:

• patients with polycystic ovarian syndrome

• patients with polycystic ovarian morphology on ultrasound

• patients who previously experienced an ovarian stimulation cycle, with a high response to gonadotrophins

Exclusion Criteria:

• patients undergoing coasting

• patients with past ovarian surgery